CN1753692A - 淋巴毒素β受体药剂与化疗剂的联合用药 - Google Patents

淋巴毒素β受体药剂与化疗剂的联合用药 Download PDF

Info

Publication number
CN1753692A
CN1753692A CNA2003801099160A CN200380109916A CN1753692A CN 1753692 A CN1753692 A CN 1753692A CN A2003801099160 A CNA2003801099160 A CN A2003801099160A CN 200380109916 A CN200380109916 A CN 200380109916A CN 1753692 A CN1753692 A CN 1753692A
Authority
CN
China
Prior art keywords
antibody
hucbe11
composition
tumor
chemotherapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801099160A
Other languages
English (en)
Chinese (zh)
Inventor
多琳·莱佩奇
艾伦·吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1753692A publication Critical patent/CN1753692A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2003801099160A 2002-12-20 2003-12-22 淋巴毒素β受体药剂与化疗剂的联合用药 Pending CN1753692A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
US60/435,185 2002-12-20

Publications (1)

Publication Number Publication Date
CN1753692A true CN1753692A (zh) 2006-03-29

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801099160A Pending CN1753692A (zh) 2002-12-20 2003-12-22 淋巴毒素β受体药剂与化疗剂的联合用药

Country Status (16)

Country Link
US (1) US20060134102A1 (https=)
EP (1) EP1585547A4 (https=)
JP (1) JP2006513225A (https=)
KR (1) KR20050094819A (https=)
CN (1) CN1753692A (https=)
AU (1) AU2003303339A1 (https=)
BR (1) BR0317573A (https=)
CA (1) CA2509495A1 (https=)
EA (1) EA200501019A1 (https=)
IS (1) IS7900A (https=)
MX (1) MXPA05006663A (https=)
NO (1) NO20053529L (https=)
PL (1) PL377611A1 (https=)
RS (1) RS20050481A (https=)
WO (1) WO2004058183A2 (https=)
ZA (1) ZA200505543B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115057938A (zh) * 2022-06-24 2022-09-16 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP2040751A2 (en) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8591886B2 (en) * 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN112912400B (zh) 2018-10-19 2025-05-30 明尼苏达大学董事会 Nk接合子分子及其使用方法
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115057938A (zh) * 2022-06-24 2022-09-16 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用
CN115057938B (zh) * 2022-06-24 2023-01-06 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Also Published As

Publication number Publication date
IS7900A (is) 2005-06-20
EP1585547A4 (en) 2006-10-25
JP2006513225A (ja) 2006-04-20
AU2003303339A1 (en) 2004-07-22
NO20053529L (no) 2005-09-20
EP1585547A2 (en) 2005-10-19
US20060134102A1 (en) 2006-06-22
WO2004058183A3 (en) 2004-12-09
BR0317573A (pt) 2005-11-22
RS20050481A (sr) 2007-08-03
ZA200505543B (en) 2006-12-27
WO2004058183A2 (en) 2004-07-15
NO20053529D0 (no) 2005-07-19
PL377611A1 (pl) 2006-02-06
EA200501019A1 (ru) 2006-06-30
MXPA05006663A (es) 2005-09-30
CA2509495A1 (en) 2004-07-15
KR20050094819A (ko) 2005-09-28

Similar Documents

Publication Publication Date Title
CN1753692A (zh) 淋巴毒素β受体药剂与化疗剂的联合用药
CN110650976B (zh) 抗SIRPα抗体
KR102493282B1 (ko) Tim3에 대한 항체 및 그의 용도
CN106459214B (zh) 用于肿瘤治疗之方法及抗体组成物
CN109963588B (zh) 抗ctla4抗体
DK2851374T3 (en) Binding molecules to the human OX40 receptor
CN105198997B (zh) Cd37免疫治疗剂及其与双功能化学治疗剂的联合
RU2551963C2 (ru) Молекулы, связывающиеся с 4-1вв
CN1798765A (zh) 多价淋巴毒素β受体激动剂及其治疗用途
DK2699598T3 (en) COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
RU2746314C2 (ru) Антитела анти-tnfrsf25
KR20150013321A (ko) Ｃｄ33 항체 및 암을 치료하기 위한 이의 용도
CN1820026A (zh) 作为选择性IFN－γ途径抑制剂的人抗IFN－γ中和性抗体
CN102167741A (zh) 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
CN113980132A (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
BRPI0813985B1 (pt) Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
JP2006513225A5 (https=)
KR20230135637A (ko) 새로운 활성을 갖는 hhla2 결합제
TW202334216A (zh) 抗cd47抗體及其使用方法
CN115244084A (zh) 抗gitr抗体及其用途
CN1435433A (zh) 长效广谱的趋化因子受体抑制物
CN115279907A (zh) 与cd3结合的双特异性抗体
AU2018202095B2 (en) Binding Molecules to the Human OX40 Receptor
HK1146415B (en) Binding molecules to the human ox40 receptor
HK1146415A (en) Binding molecules to the human ox40 receptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060329